NCT02637310

Evaluate the Efficacy and Safety of N02RS1 in Patient With Acute Bronchitis

A Multi Center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2b Clinical Trial to Evaluate the Efficacy and Safety of N02RS1 in Patients With Acute Bronchitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 108 (actual)
• Sponsor: PharmaKing · Industry
• Sex: All
• Age: 19 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A multi center, randomized, double-blind, placebo-controlled, parallel, phase 2b clinical trial to evaluate the efficacy and safety of N02RS1 in patients with acute bronchitis

Detailed description

Suitable subjects randomized to the experimental or control group. The subjects eat IP during 7days. Visit 3(3 days) evaluate BSS through phone call and visit 4(8 days) evaluate efficacy and safety.

Conditions

• Acute Bronchitis

Interventions

Type	Name	Description
DRUG	N02RS1 1200mg	1200mg/day, Three times a day orally, 2 tablets once, 7 days
DRUG	Placebo	1200mg/day, Three times a day orally, 2 tablets once, 7 days

Timeline

• Start date: 2015-12-01
• Primary completion: 2016-03-01
• Completion: 2016-03-01
• First posted: 2015-12-22
• Last updated: 2016-03-30